A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
Completed
Washington University School of Medicine
N/A
1969-12-31
To evaluate the effectiveness and safety of amphotericin B plus flucytosine
(5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal
meningitis in AIDS patients, and to compare the effectiveness and safety of fluconazole
versus itraconazole.
At least 10 percent of patients with a low CD4 count and HIV infection will develop
meningitis due to Cryptococcus neoformans. More effective treatments than the standard
therapy need to be explored.
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
N/A
1969-12-31
To evaluate the effectiveness and safety of amphotericin B plus flucytosine
(5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal
meningitis in AIDS patients, and to compare the effectiveness and safety of fluconazole
versus itraconazole.
At least 10 percent of patients with a low CD4 count and HIV infection will develop
meningitis due to Cryptococcus neoformans. More effective treatments than the standard
therapy need to be explored.
Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
N/A
1969-12-31
To compare the safety and effectiveness of fluconazole (FCZ) and amphotericin B (AMB), alone
or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis in
patients who have not been treated previously or who have relapsed after a previous
successful treatment.
Cryptococcal meningitis is an important cause of disease and death among patients with AIDS.
Usually AMB is given either alone or with FLC to patients with this infection, but these
treatments are not always effective and both have toxic effects. Animal studies and
preliminary studies in humans show that FCZ is active in cryptococcal meningitis and suggest
that it may be less toxic than either AMB or FLC.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
